The use of an aromatase inhibitor (AI) to prevent elevated E2 exposure in breast cancer fertility preservation (FP) patients results in a lower oocyte maturity rate despite larger follicles

      Despite a lack of evidence that brief exposure to elevated E2 affects prognosis, it has become standard to use an AI throughout the entire follicular stimulation when treating breast cancer FP patients in an effort to reduce E2 levels. However, AIs alter traditional stimulation markers such as E2 and follicular size and may complicate clinical decision making. This study seeks to determine whether continuous AI use throughout stimulation impacts oocyte maturity and function.
      To read this article in full you will need to make a payment


      Subscribe to Fertility and Sterility
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect